ENSG00000291006 and ovarian carcinoma: To further identify the mechanism of action by which LOC730101 promotes increased drug sensitivity in ovarian cancer cells, immunofluorescence assays combined with confocal observation revealed that after treatment of ovarian cancer cells with cisplatin or niraparib drugs, respectively, the DNA damage marker γ-H2AX focus was reduced in ovarian cancer cells with LOC730101 knock down compared to the control group (Fig. 7A, B).